Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio |
|
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients |
|
Benefit of farnesoid X receptor inhibition in obstructive cholestasis |
|
Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia |
|
A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. |
|
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. |
|
Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice |
|
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study |
|
Hepatobiliary ABC transporters: physiology, regulation and implications for disease. |
|
Herbal hepatotoxicity |
|
Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand |
|
Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis |
|
Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand |
|
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury |
|
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial |
|
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs |
|
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy |
|
Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study |
|
Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs |
|
Reply: To PMID 21994151 |
|
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease |
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection |
|
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen |
|
Transient elastography to assess liver stiffness in patients with inflammatory bowel disease |
|
Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis |
|
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction |
|